05:11 PM EDT, 04/03/2024 (MT Newswires) -- iRadimed (IRMD) on Wednesday filed a registration statement with the US Securities and Exchange Commission covering the potential sale of up to $75 million of its common stock from time to time in one or more offerings.

The company said it intends to use the net proceeds to accelerate research and development and general corporate purposes such as working capital, capital expenditures, and operational purposes. It may use a portion of net proceeds to acquire or invest in businesses, products, or complementary technologies.

Shares of the company fell 1.8% in after-hours activity.

Price: 41.54, Change: -0.77, Percent Change: -1.82